Data from multiple sources - Curated by Toby Galbraith - Last updated 04 January 2017
Latest news articles
Added 5 days ago Drug news
Medtronic launches DxTerity Diagnostic Angiography Catheter line for use in diagnostic cardiac catheterization procedures and percutaneous coronary intervention.
Medtronic plc has announced that its market-leading coronary portfolio will now include the DxTerity Diagnostic Angiography Catheter line and several...
Added 3 months ago Drug news
Corindus Vascular Robotics Inc. has received 510(k) clearance from the FDA for its CorPath GRX Vascular Robotic System for Percutaneous Coronary Interventions.
Corindus Vascular Robotics (Corindus) has received 510(k) clearance from the FDA for its CorPath GRX, the second generation of its...
Added 6 months ago Drug news
NICE recommends use of Brilique (ticagrelor) at reduced dose of 60 mg to reduce risk of heart attack.- AstraZeneca
The National Institute for Care and Health Excellence has recommended the use of Brilique (ticagrelor) from AstraZeneca at a lower...
An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.
Knowledge of the risks associated with CVD during pregnancy and their management are of pivotal importance for advising patients before...
Added 5 years ago
Testosterone treatment is not associated with increased risk of adverse cardiovascular events: results from the Registry of Hypogonadism in Men (RHYME).
The aim of this study was to assess cardiovascular (CV) safety of testosterone replacement therapy (TRT) in a large, diverse cohort of European men with hypogonadism (HG).
Added 2 months ago
Effects of P2Y12 receptor antagonists beyond platelet inhibition - comparison of ticagrelor with thienopyridines.
The effect and clinical benefit of P2Y12 receptor antagonists may not be limited to platelet inhibition and the prevention of...
Added 10 months ago
Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial.
Importance: Few cardiovascular outcomes trials have been conducted for obesity treatments. Withdrawal of 2 marketed drugs has resulted in controversy...
Added 11 months ago